Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.24 USD | +3.17% | +1.77% | -44.78% |
04-23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
04-22 | Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada | MT |
Turnover - Change in analysts' estimates
Earnings Per Share (EPS) - Change in analysts' estimates
EBIT - Change in analysts' estimates
Dividend / Share (DPS) - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Equities
- ACAD Stock
- Revisions ACADIA Pharmaceuticals Inc.